Vetigenics is transforming personalized healthcare for pets while driving advancements in human medicine. Their state-of-the-art phage display platform enables them to rapidly produce entirely canine antibodies or CANIBODIES™ that are the building blocks for monoclonal and bispecific antibodies, CAR T-cells, and more. Their novel technology has successfully generated antibodies for both dogs and cats across a wide range of therapeutic areas.
Vetigenics commissioned Axxiem to redesign their existing biotech website and clearly explain their propriety CANIBODY™ Platform.
